A Phase 4 interventional study of Intravitreal Aflibercept Injection (IAI) in Chorioretinal Vascular Disease, sponsored by Regeneron Pharmaceuticals. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-16.
Sponsored by Regeneron Pharmaceuticals · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to determine if the pre-filled syringe (PFS) supports successful preparation and accurate administration of an aflibercept injection.
The secondary objective of the study is to assess ocular safety in the study eye.
Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other inclusion/ exclusion apply
Cohort 1 - Initial patients Cohort 2 - Additional patients
Drug: Intravitreal Aflibercept Injection (IAI)
IAI prepared and administered with a pre-filled syringe (PFS)
Also known as: Aflibercept, EYLEA®
Number of Aflibercept Injections Successfully Administered Utilizing the Prefilled Syringe (PFS)
Participants received a single dose of study drug, administered in the selected study eye with the PFS by a retina specialist. Physician assessed successful aflibercept preparation and administration with the PFS.
Time frame: At Day 1
Incidence of Ocular Treatment-Emergent Adverse Events (TEAEs) of Study Eye Through Day 29
A treatment emergent AE (TEAE) is an adverse event starting after study eye injection and no later than 28 days after administration of study medication.
Time frame: Baseline through Day 29
Incidence of Ocular Serious TEAEs of Study Eye Through Day 29
A serious treatment emergent AE (TEAE) is a serious adverse event starting after study eye injection and no later than 28 days after administration of study medication.
Time frame: Baseline through Day 29
A total of 65 participants were enrolled in the United States.
| Milestone | Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg | Cohort 2: IAI 2 mg |
|---|---|---|
| Started | 35 | 30 |
| Completed | 35 | 30 |
| Not completed | 0 | 0 |
Participants received a single dose of study drug, administered in the selected study eye with the PFS by a retina specialist. Physician assessed successful aflibercept preparation and administration with the PFS.
| Injections | Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg | Cohort 2: IAI 2 mg |
|---|---|---|
| Number of Aflibercept Injections Successfully Administered Utilizing the Prefilled Syringe (PFS) | 35 | 29 |
A treatment emergent AE (TEAE) is an adverse event starting after study eye injection and no later than 28 days after administration of study medication.
| Events | Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg | Cohort 2: IAI 2 mg |
|---|---|---|
| Conjunctival haemorrhage | 3 | 1 |
| Eye irritation | 3 | 0 |
| Dry eye | 0 | 1 |
| Eye pain | 0 | 1 |
| Lenticular opacities | 0 | 1 |
| Corneal abrasion | 1 | 0 |
A serious treatment emergent AE (TEAE) is a serious adverse event starting after study eye injection and no later than 28 days after administration of study medication.
| Events | Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg | Cohort 2: IAI 2 mg |
|---|---|---|
| Incidence of Ocular Serious TEAEs of Study Eye Through Day 29 | 0 | 0 |
Collected over Up to Day 29. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg | 0/35 (0%) | 1/35 (2.9%) | 6/35 (17.1%) |
| Cohort 2: IAI 2 mg | 0/30 (0%) | 0/30 (0%) | 1/30 (3.3%) |
| Event | Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg | Cohort 2: IAI 2 mg |
|---|---|---|
| Iron deficiency anaemiaBlood and lymphatic system disorders | 1/35 | 0/30 |
| Event | Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg | Cohort 2: IAI 2 mg |
|---|---|---|
| Conjunctival haemorrhage Study EyeEye disorders | 3/35 | 1/30 |
| Eye irritation Study EyeEye disorders | 3/35 | 0/30 |
| Age, Continuous(Years) | Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg | Cohort 2: IAI 2 mg | Total |
|---|---|---|---|
| Mean | 72.2 ± 10.04 | 64.7 ± 13.44 | 68.8 ± 12.23 |
| Sex: Female, Male(Participants) | Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg | Cohort 2: IAI 2 mg | Total |
|---|---|---|---|
| Female | 20 | 14 | 34 |
| Male | 15 | 16 | 31 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg | Cohort 2: IAI 2 mg | Total |
|---|---|---|---|
| Hispanic or Latino | 3 | 4 | 7 |
| Not Hispanic or Latino | 32 | 26 | 58 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Cohort 1: Intravitreal Aflibercept Injection (IAI) 2 mg | Cohort 2: IAI 2 mg | Total |
|---|---|---|---|
| White | 32 | 25 | 57 |
| Black or African American | 3 | 3 | 6 |
| Asian | 0 | 1 | 1 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Other | 0 | 1 | 1 |
| Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2018 to primary completion in Aug 2020, 20 months.
Results were first posted in Sep 2021, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Aflibercept